Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 228-973-9 | CAS number: 6381-77-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Remarks:
- combined repeated dose and carcinogenicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Basic information provided
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Final Report on the Safety Assessment of Ascorbyl Palmitate, Ascorbyl Dipalmitate, Ascorbyl Stearate, Erythorbic Acid, and sodium Erythorbate
- Author:
- F. Alan Andersen, Cosmetic Ingredient Expert Review Panel
- Year:
- 1 999
- Bibliographic source:
- International Journal of Toxicology 1999 18 (suppl. 3): 1-26
- Reference Type:
- publication
- Title:
- Tumorigenicity study of sodium erythorbate administered orally to mice.
- Author:
- Inai K, Akamizu H, Eto R, Nishida T, Ohe K, Kobuke T, Nambu S, Matsuki K, Tokuoka S.
- Year:
- 1 989
- Bibliographic source:
- Hiroshima J Med Sci. Sep;38(3):135-9.
Materials and methods
- Principles of method if other than guideline:
- Preliminary test: Male and female B6C3F1 mice (10 per sex per group) were given drinking water containing 0.625%, 1.25%, 2.5%, 5.0%, or 10% Sodium Erythrobate for 10 weeks. Water and feed were available ad libitum. The untreated control group consisted of 20 male and 20 female mice. Mortality, bodyweight gain, gross pathology and histopathology were noted.
Main test: Sodium Erythorbate was administered in drinking water to male B6C3Fi mice at concentrations of 1.25% and 2.5%.
Female mice received 2.5% and 5% (MTD). Each group contained 50 mice. Treatment continued for 96 weeks; the study was terminated at week 110. Feed and water were available ad libitum. Mortality, body weight, organ weights and neoplastic histopathology were noted. - GLP compliance:
- not specified
Test material
- Reference substance name:
- 2,3-didehydro-3-O-sodio-D-erythro-hexono-1,4-lactone
- EC Number:
- 228-973-9
- EC Name:
- 2,3-didehydro-3-O-sodio-D-erythro-hexono-1,4-lactone
- Cas Number:
- 6381-77-7
- Molecular formula:
- C6H8O6.Na
- IUPAC Name:
- sodium (2R)-2-[(1R)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate
- Test material form:
- other: in drinking water
- Details on test material:
- - Name of test material (as cited in study report):Sodium erythorbate
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- B6C3F1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Diet: ad libitum
- Water: ad libitum
Administration / exposure
- Route of administration:
- oral: drinking water
- Vehicle:
- water
- Duration of treatment / exposure:
- Preliminary study: 10 weeks
Main study: 96 weeks
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0.625%, 1.25%, 2.5%, 5.0%, or 10%
Basis:
other: Preliminary test
- Remarks:
- Doses / Concentrations:
1.25%, 2.5%
Basis:
other: Main test (Males)
- Remarks:
- Doses / Concentrations:
2.5%, 5.0%
Basis:
other: Main test (Females)
- No. of animals per sex per dose:
- Preliminary study: 10 males and 10 females for test substance; 20 males and 20 females for untreated controls
Main study: 50 males (1.25%, 2.5%) and 50 females (2.5%, 5.0%) - Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- BODY WEIGHT: Yes (Preliminary and main study)
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes (Main study) - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (Preliminary and main study)
HISTOPATHOLOGY: Yes (Preliminary and main study)
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Preliminary study: By the end of the 1st week of treatment, six male mice and one female mouse of the 10% dosing group had died.
BODY WEIGHT AND WEIGHT GAIN
Preliminary study: In male mice given 5.0% Sodium Erythrobate, the average weekly body weight gain was slightly less than 90% that of the control female mice. Body weight gain was increased in female mice given Sodium Erythrobate at a concentration of 5.0%, compared to that of control mice.
Main study: The average body weights of the treated mice were similar to controls.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study)
Main study: No significant difference was observed between groups in the amount of water intake. As a consequence, the males in the high dose group received a dose of Sodium Erythorbate that was approximately 1.5 times greater than that of the low-dose group. For the female groups, Sodium Erythorbate intake by the high-dose group was approximately 1.8 times greater than that of the low-dose group.
ORGAN WEIGHTS
Main study: Of the male mice (without tumors) that survived beyond week 43, dose-dependent reductions in the heart and brain weights were observed. The weights of the heart, lungs, kidneys, and brain of female mice (without tumors) were significantly different between the high dose group and the control group.
GROSS PATHOLOGY
Preliminary study: No significant changes were observed in the visceral organs of untreated mice or mice given the dose less than or equal to the MTD of Sodium Erythrobate
HISTOPATHOLOGY: NON-NEOPLASTIC
Preliminary study: Mice given doses greater than the MTD had marked atrophy of both hepatocytes and splenic lymphoid follicles, as well as hydropic degeneration of the renal tubular epithelium.
HISTOPATHOLOGY: NEOPLASTIC
Main study: The tumors observed in the male mice were hepatocellular tumors, subcutaneous sarcoma, adenoma and carcinoma of the lungs, and lymphoma/leukemia. The time-adjusted analysis of tumor incidence was performed on the hepatocellular tumors and subcutaneous sarcomas, the incidence of which was significant. The lymphoma/leukemia had the highest incidence in female mice treated with Sodium Erythorbate, but this was not significant. Overall, tumor incidence, time to death with tumors, and the distribution of tumors in treated mice did not differ significantly from mice of the control group.
Effect levels
open allclose all
- Dose descriptor:
- dose level: Maximum Tolerated Dose (MTD)
- Effect level:
- 2.5 other: %
- Sex:
- male
- Basis for effect level:
- other: Preliminary study
- Dose descriptor:
- dose level: Maximum Tolerated Dose (MTD)
- Effect level:
- 5 other: %
- Sex:
- female
- Basis for effect level:
- other: Preliminary study
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Executive summary:
In a repeated dose and carcinogenicity study, 2,3-didehydro-3-O-sodio-D-erythro-hexono-1,4-lactone was administered to 10 B6C3F1 mice/sex/dose in drinking water at dose levels of 0, 0.625, 1.25, 2.5, 5 and 10% for 10 weeks (preliminary study) and then to 50 B6C3F1 mice in water at dose levels of 1.25 and 2.5% (males) and 2.5 and 5% (females) for 96 weeks (main study).
In the preliminary study, six male mice and one female mouse of the 10% dosing group had died by the end of week 1. In male mice given 5.0% Sodium Erythrobate, the average weekly body weight gain was slightly less than 90% that of the control female mice. Body weight gain was increased in female mice given Sodium Erythrobate at a concentration of 5.0%, compared to that of control mice. No significant changes were observed in the visceral organs of untreated mice or mice given the dose less than or equal to the maximum tolerated dose (MTD) of Sodium Erythrobate. Mice given doses greater than the MTD had marked atrophy of both hepatocytes and splenic lymphoid follicles, as well as hydropic degeneration of the renal tubular epithelium. The MTD of Sodium Erythrobate in drinking water was 2.5% for male mice and 5.0% for female mice.
In the main study, the average body weights of the treated mice were similar to controls. Of the male mice (without tumors) that survived beyond week 43, dose-dependent reductions in the heart and brain weights were observed. The weights of the heart, lungs, kidneys, and brain of female mice (without tumors) were significantly different between the high dose group and the control group.At the doses tested, there was not a treatment related increase in tumor incidence when compared to controls. Overall, tumor incidence, time to death with tumors, and the distribution of tumors in treated mice did not differ significantly from mice of the control group.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.